4.7 Review

Is There a Glutathione Centered Redox Dysregulation Subtype of Schizophrenia?

期刊

ANTIOXIDANTS
卷 10, 期 11, 页码 -

出版社

MDPI
DOI: 10.3390/antiox10111703

关键词

glutathione; glutamate; psychosis; schizophrenia; redox; antioxidant; oxidative stress; myelin; spectroscopy

资金

  1. Tanna Schulich Chair of Neuroscience and Mental Health
  2. CIHR Foundation [375104/2017]
  3. NSERC [RGPIN2016-05055]
  4. Canada First Excellence Research Fund
  5. Western University
  6. Compute Canada Resources
  7. National Institutes of Mental Health [MH-092443, MH-094268, MH-105660, MH-107730]
  8. Stanley
  9. RUSK/S-R
  10. Brain and Behavior Research Foundation

向作者/读者索取更多资源

Schizophrenia is a disease with poor outcome, with mechanistic changes occurring years before the onset that may still be modifiable, particularly in relation to intracortical glutathione. Recent magnetic resonance spectroscopic studies have linked GSH to critical outcome measures across various stages of schizophrenia.
Schizophrenia continues to be an illness with poor outcome. Most mechanistic changes occur many years before the first episode of schizophrenia; these are not reversible after the illness onset. A developmental mechanism that is still modifiable in adult life may center on intracortical glutathione (GSH). A large body of pre-clinical data has suggested the possibility of notable GSH-deficit in a subgroup of patients with schizophrenia. Nevertheless, studies of intracortical GSH are not conclusive in this regard. In this review, we highlight the recent ultra-high field magnetic resonance spectroscopic studies linking GSH to critical outcome measures across various stages of schizophrenia. We discuss the methodological steps required to conclusively establish or refute the persistence of GSH-deficit subtype and clarify the role of the central antioxidant system in disrupting the brain structure and connectivity in the early stages of schizophrenia. We propose in-vivo GSH quantification for patient selection in forthcoming antioxidant trials in psychosis. This review offers directions for a promising non-dopaminergic early intervention approach in schizophrenia.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.7
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据